$7.2 Billion In Crypto Token Unlocks Expected To Shake Markets This January
A crypto research platform anticipates that several cryptocurrency tokens will be unlocked within January this year with an estimated value […]
January 7, 2025
biotech firm’s stock rides on avutometinib approval By Investing.com
Verastem Inc (NASDAQ:), a biopharmaceutical company with a market capitalization of $289 million focused on developing treatments for cancer patients,
Report outlines concerning effects of crypto assets — ‘immediate transparency’ is needed
In the time since a 2022 report by the White House warned of cryptocurrency’s energy costs and negative impacts on
stock soars amid favorable trading landscape By Investing.com
Marex Group PLC (MRX), a prominent player in the Exchange, Trading & eBroker sector, has been making waves in the
US Prosecutors Estimate Over 1 Million Victims in Do Kwon Crypto Fraud Case
U.S. prosecutors pursuing criminal charges against Terraform Labs co-founder Do Kwon have estimated that the collapse of the TerraUSD and
oncology biotech’s stock faces pivotal year By Investing.com
CytomX Therapeutics (NASDAQ:), a clinical-stage biopharmaceutical company with a market capitalization of $79.75 million, focuses on developing novel cancer treatments
SOL holds $205 support as crypto market tumbles on US jobs data
Solana price plunges 6.4% to find support at $205 on Tuesday, stronger than expected US jobs data sparked rapid liquidations
stock faces headwinds amid growth potential By Investing.com
Array Technologies, Inc. (NASDAQ:ARRY), a player in the clean energy solutions sector, has been navigating a complex landscape of challenges
Crypto.com ups Matt David NA president, corporate affairs lead
TYLER, TX: Crypto.com has promoted Matt David to chief corporate affairs officer and president of North America, as the cryptocurrency
oncology biotech stock’s potential and risks By Investing.com
IDEAYA Biosciences, Inc. (NASDAQ:), a biotechnology company focused on targeted therapies for cancer, has been garnering attention from analysts and